References
Key articles
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colorectal cancer screening [internet publication].Full text
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: rectal cancer [internet publication].Full text
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer [internet publication].Full text
Reference articles
1. Siegel RL, Wagle NS, Cercek A, et al. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023 May-Jun;73(3):233-54.Full text Abstract
2. American College of Surgeons. AJCC version 9 cancer staging system. 2024 [internet publication].Full text
3. Eng C, Yoshino T, Ruíz-García E, et al. Colorectal cancer. Lancet. 2024 Jul 20;404(10449):294-310. Abstract
4. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Cancer stat facts: colorectal cancer. 2023 [internet publication].Full text
5. American Cancer Society. Cancer facts and figures 2025. 2025 [internet publication].Full text
6. American Cancer Society. Cancer facts and figures 2024. 2024 [internet publication].Full text
7. GBD 2019 Colorectal Cancer Collaborators. Global, regional, and national burden of colorectal cancer and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022 Jul;7(7):627-47.Full text Abstract
8. American Cancer Society. Colorectal cancer facts and figures, 2023-2025. 2023 [internet publication].Full text
9. Dai R, Kelly BN, Ike A, et al. The impact of the gut microbiome, environment, and diet in early-onset colorectal cancer development. Cancers (Basel). 2024 Feb 5;16(3):676.Full text Abstract
10. Li S, Keenan JI, Shaw IC, et al. Could microplastics be a driver for early onset colorectal cancer? Cancers (Basel). 2023 Jun 24;15(13):3323.Full text Abstract
11. Fedewa SA, Flanders WD, Ward KC, et al. Racial and ethnic disparities in interval colorectal cancer incidence: a population-based cohort study. Ann Intern Med. 2017 Jun 20;166(12):857-66. Abstract
12. Parente F, Bargiggia S, Boemo C, et al. Anatomic distribution of cancers and colorectal adenomas according to age and sex and relationship between proximal and distal neoplasms in an i-FOBT-positive average-risk Italian screening cohort. Int J Colorectal Dis. 2014 Jan;29(1):57-64. Abstract
13. Kim SE, Paik HY, Yoon H, et al. Sex- and gender-specific disparities in colorectal cancer risk. World J Gastroenterol. 2015 May 7;21(17):5167-75.Full text Abstract
14. Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer. 2006 Jan;42(2):216-27. Abstract
15. Song M, Emilsson L, Roelstraete B, et al. Risk of colorectal cancer in first degree relatives of patients with colorectal polyps: nationwide case-control study in Sweden. BMJ. 2021 May 4;373:n877.Full text Abstract
16. Jasperson KW, Tuohy TM, Neklason DW, et al. Hereditary and familial colon cancer. Gastroenterology. 2010 Jun;138(6):2044-58.Full text Abstract
17. Ma H, Brosens LA, Offerhaus GJ, et al. Pathology and genetics of hereditary colorectal cancer. Pathology. 2017 Nov 21;50(1):49-59. Abstract
18. Dong Y, Zhou J, Zhu Y, et al. Abdominal obesity and colorectal cancer risk: systematic review and meta-analysis of prospective studies. Biosci Rep. 2017 Dec 12;37(6):BSR20170945.Full text Abstract
19. Wong MC, Chan CH, Cheung W, et al. Association between investigator-measured body-mass index and colorectal adenoma: a systematic review and meta-analysis of 168,201 subjects. Eur J Epidemiol. 2017 Dec 29;33(1):15-26.Full text Abstract
20. Hidayat K, Yang CM, Shi BM. Body fatness at an early age and risk of colorectal cancer. Int J Cancer. 2018 Feb 15;142(4):729-40.Full text Abstract
21. Mandic M, Li H, Safizadeh F, et al. Is the association of overweight and obesity with colorectal cancer underestimated? An umbrella review of systematic reviews and meta-analyses. Eur J Epidemiol. 2023 Feb;38(2):135-44.Full text Abstract
22. Bardou M, Rouland A, Martel M, et al. Review article: obesity and colorectal cancer. Aliment Pharmacol Ther. 2022 Aug;56(3):407-18.Full text Abstract
23. Liu PH, Wu K, Ng K, et al. Association of obesity with risk of early-onset colorectal cancer among women. JAMA Oncol. 2019 Jan 1;5(1):37-44.Full text Abstract
24. Pararas N, Pikouli A, Dellaportas D, et al. The protective effect of bariatric surgery on the development of colorectal cancer: a systematic review and meta-analysis. Int J Environ Res Public Health. 2023 Feb 23;20(5):3981.Full text Abstract
25. Davey MG, Ryan OK, Ryan ÉJ, et al. The impact of bariatric surgery on the incidence of colorectal cancer in patients with obesity-a systematic review and meta-analysis of registry data. Obes Surg. 2023 Aug;33(8):2293-302.Full text Abstract
26. Chierici A, Amoretti P, Drai C, et al. Does bariatric surgery reduce the risk of colorectal cancer in individuals with morbid obesity? a systematic review and meta-analysis. Nutrients. 2023 Jan 16;15(2):467.Full text Abstract
27. Janik MR, Clapp B, Sroczyński P, et al. The effect of bariatric surgery on reducing the risk of colorectal cancer: a meta-analysis of 3,233,044 patients. Surg Obes Relat Dis. 2023 Apr;19(4):328-34. Abstract
28. Bustamante-Lopez L, Sulbaran M, Changoor NR, et al. Impact of bariatric surgery on early-onset colorectal cancer risk: a systematic review and meta-analysis. Updates Surg. 2023 Aug;75(5):1051-7. Abstract
29. Mao Y, Pan S, Wen SW, et al; Canadian Cancer Registries Epidemiology Research Group. Physical inactivity, energy intake, obesity and the risk of rectal cancer in Canada. Int J Cancer. 2003 Jul 20;105(6):831-7. Abstract
30. Wolin KY, Yan Y, Colditz GA, Lee IM. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer. 2009 Feb 24;100(4):611-6.Full text Abstract
31. Farvid MS, Sidahmed E, Spence ND, et al. Consumption of red meat and processed meat and cancer incidence: a systematic review and meta-analysis of prospective studies. Eur J Epidemiol. 2021 Sep;36(9):937-51. Abstract
32. Bouvard V, Loomis D, Guyton KZ, et al. Carcinogenicity of consumption of red and processed meat. Lancet Oncol. 2015 Dec;16(16):1599-600. Abstract
33. Hammerling U, Bergman Laurila J, Grafström R, et al. Consumption of red/processed meat and colorectal carcinoma: possible mechanisms underlying the significant association. Crit Rev Food Sci Nutr. 2016;56(4):614-34. Abstract
34. Huang J, Pan G, Jiang H, et al. A meta-analysis between dietary carbohydrate intake and colorectal cancer risk: evidence from 17 observational studies. Biosci Rep. 2017 Apr 10;37(2):BSR20160553.Full text Abstract
35. Ferguson LR, Harris PJ. The dietary fibre debate: more food for thought. Lancet. 2003 May 3;361(9368):1487-8. Abstract
36. Song M, Wu K, Meyerhardt JA, et al. Fiber intake and survival after colorectal cancer diagnosis. JAMA Oncol. 2018 Jan 1;4(1):71-9.Full text Abstract
37. Ma Y, Hu M, Zhou L, et al. Dietary fiber intake and risks of proximal and distal colon cancers: a meta-analysis. Medicine (Baltimore). 2018 Sep;97(36):e11678.Full text Abstract
38. Arayici ME, Mert-Ozupek N, Yalcin F, et al. Soluble and insoluble dietary fiber consumption and colorectal cancer risk: a systematic review and meta-analysis. Nutr Cancer. 2022;74(7):2412-25. Abstract
39. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colorectal cancer screening [internet publication].Full text
40. Chao A, Thun MJ, Jacobs EJ, et al. Cigarette smoking and colorectal cancer mortality in the cancer prevention study II. J Natl Cancer Inst. 2000 Dec 6;92(23):1888-96.Full text Abstract
41. Hannan LM, Jacobs EJ, Thun MJ. The association between cigarette smoking and risk of colorectal cancer in a large prospective cohort from the United States. Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3362-7.Full text Abstract
42. Fedirko V, Tramacere I, Bagnardi V, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann Oncol. 2011 Sep;22(9):1958-72.Full text Abstract
43. O'Sullivan DE, Sutherland RL, Town S, et al. Risk factors for early-onset colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022 Jun;20(6):1229-40.e5.Full text Abstract
44. Hernández-Alonso P, Boughanem H, Canudas S, et al. Circulating vitamin D levels and colorectal cancer risk: a meta-analysis and systematic review of case-control and prospective cohort studies. Crit Rev Food Sci Nutr. 2023;63(1):1-17.Full text Abstract
45. Botteri E, Borroni E, Sloan EK, et al. Smoking and colorectal cancer risk, overall and by molecular subtypes: a meta-analysis. Am J Gastroenterol. 2020 Dec;115(12):1940-9. Abstract
46. Rossi M, Jahanzaib Anwar M, Usman A, et al. Colorectal cancer and alcohol consumption-populations to molecules. Cancers (Basel). 2018 Jan 30;10(2):38.Full text Abstract
47. Hryhorowicz S, Kaczmarek-Ryś M, Lis-Tanaś E, et al. Strong hereditary predispositions to colorectal cancer. Genes (Basel). 2022 Dec 10;13(12):2326.Full text Abstract
48. Arnold CN, Goel A, Blum HE, et al. Molecular pathogenesis of colorectal cancer. Cancer. 2005 Nov 15;104(10):2035-47.Full text Abstract
49. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010 Jun;138(6):2059-72.Full text Abstract
50. Sinicrope FA, Sargent DJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res. 2012 Mar 15;18(6):1506-12.Full text Abstract
51. Nazemalhosseini Mojarad E, Kuppen PJ, Aghdaei HA, et al. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol Hepatol Bed Bench. 2013 Summer;6(3):120-8. Abstract
52. Plawski A, Banasiewicz T, Borun P et al. Familial adenomatous polyposis of the colon. Hered Cancer Clin Pract. 2013 Oct 22;11:15.Full text
53. Parker TW, Neufeld KL. APC controls Wnt-induced β-catenin destruction complex recruitment in human colonocytes. Sci Rep. 2020 Feb 19;10(1):2957.Full text Abstract
54. Saravani K, Salarzaei M, Parooie F. Effect of KRAS and BRAF mutations in metastatic colorectal cancer patients: a systematic review and meta-analysis based on tumor sidedness and KRAS subtypes. Hum Antibodies. 2021;29(4):275-84.Full text Abstract
55. Strickler JH, Yoshino T, Stevinson K, et al. Prevalence of KRAS G12C mutation and co-mutations and associated clinical outcomes in patients with colorectal cancer: a systematic literature review. Oncologist. 2023 Nov 2;28(11):e981-94.Full text Abstract
56. Christensen TD, Spindler KL, Palshof JA, et al. Systematic review: brain metastases from colorectal cancer - incidence and patient characteristics. BMC Cancer. 2016 Apr 1;16:260.Full text Abstract
57. Raphael MJ, Karanicolas PJ. Regional therapy for colorectal cancer liver metastases: which modality and when? J Clin Oncol. 2022 Aug 20;40(24):2806-17.Full text Abstract
58. Issaka RB, Chan AT, Gupta S. AGA clinical practice update on risk stratification for colorectal cancer screening and post-polypectomy surveillance: expert review. Gastroenterology. 2023 Nov;165(5):1280-91.Full text Abstract
59. American College of Obstetricians and Gynecologists. Practice bulletin no. 147: lynch syndrome. Nov 2014 [internet publication].Full text
60. Peltomäki P, Nyström M, Mecklin JP, et al. Lynch syndrome genetics and clinical implications. Gastroenterology. 2023 Apr;164(5):783-99.Full text Abstract
62. Meyers M, Theodosiou M, Acharya S, et al. Cell cycle regulation of the human DNA mismatch repair genes hMSH2, hMLH1, and hPMS2. Cancer Res. 1997 Jan 15;57(2):206-8. Abstract
63. Wang Q, Lasset C, Desseigne F, et al. Prevalence of germline mutations of hMLH1, hMSH2, hPMS1, hPMS2, and hMSH6 genes in 75 French kindreds with nonpolyposis colorectal cancer. Hum Genet. 1999 Jul-Aug;105(1-2):79-85. Abstract
64. Fu L, Sheng JQ, Li XO, et al. Mismatch repair gene mutation analysis and colonoscopy surveillance in Chinese Lynch syndrome families. Cell Oncol (Dordr). 2013 Jun;36(3):225-31. Abstract
65. De Jong AE, Morreau H, Van Puijenbroek M, et al. The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology. 2004 Jan;126(1):42-8. Abstract
66. Yamamoto H, Imai K. Microsatellite instability: an update. Arch Toxicol. 2015 Feb 22;89(6):899-921. Abstract
67. Nielsen M, Morreau H, Vasen HF, et al. MUTYH-associated polyposis (MAP). Crit Rev Oncol Hematol. 2011 Jul;79(1):1-16. Abstract
68. Kidambi TD, Kohli DR, Samadder NJ, et al. Hereditary polyposis syndromes. Curr Treat Options Gastroenterol. 2019 Dec;17(4):650-65. Abstract
69. Giardiello FM, Bresinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000 Dec;119(6):1447-53. Abstract
70. Bopanna S, Ananthakrishnan AN, Kedia S, et al. Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017 Feb 21;2(4):269-76.Full text Abstract
71. Castaño-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014 Apr;39(7):645-59.Full text Abstract
72. Jess T, Gamborg M, Matzen P, et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005 Dec;100(12):2724-9. Abstract
73. Gilat T, Fireman Z, Grossman A, et al. Colorectal cancer in patients with ulcerative colitis. A population study in central Israel. Gastroenterology. 1988 Apr;94(4):870-7. Abstract
74. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001 Apr;48(4):526-35.Full text Abstract
75. Dworakowska D, Grossman AB. Colonic cancer and acromegaly. Front Endocrinol (Lausanne). 2019;10:390.Full text Abstract
76. Dal J, Leisner MZ, Hermansen K, et al. Cancer incidence in patients with acromegaly: a cohort study and meta-analysis of the literature. J Clin Endocrinol Metab. 2018 Jun 1;103(6):2182-8.Full text Abstract
77. Kruk J, Aboul-Enein HY. Physical activity and cancer prevention: updating the evidence. The role of oxidative stress in carcinogenesis. Curr Cancer Ther Rev. 2007;3(2):81-95.
78. Wu W, Guo F, Ye J, et al. Pre- and post-diagnosis physical activity is associated with survival benefits of colorectal cancer patients: a systematic review and meta-analysis. Oncotarget. 2016 Aug 9;7(32):52095-103.Full text Abstract
79. Shami JJP, Zhao J, Pathadka S, et al. Safety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study. BMJ Open. 2022 Feb 4;12(2):e050510.Full text Abstract
80. Sikavi DR, Wang K, Ma W, et al. Aspirin use and incidence of colorectal cancer according to lifestyle risk. JAMA Oncol. 2024 Oct 1;10(10):1354-61. Abstract
81. Lloyd KE, Hall LH, King N, et al. Aspirin use for cancer prevention: a systematic review of public, patient and healthcare provider attitudes and adherence behaviours. Prev Med. 2022 Jan;154:106872.Full text Abstract
82. Guo CG, Ma W, Drew DA, et al. Aspirin use and risk of colorectal cancer among older adults. JAMA Oncol. 2021 Mar 1;7(3):428-35. Abstract
83. Guirguis-Blake JM, Evans CV, Perdue LA, et al. Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022 Apr 26;327(16):1585-97.Full text Abstract
84. Shaukat A, Kahi CJ, Burke CA, et al. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol. 2021 Mar 1;116(3):458-79.Full text Abstract
85. Cook NR, Lee IM, Zhang SM, et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013 Jul 16;159(2):77-85.Full text Abstract
86. Emilsson L, Holme Ø, Bretthauer M, et al. Systematic review with meta-analysis: the comparative effectiveness of aspirin vs. screening for colorectal cancer prevention. Aliment Pharmacol Ther. 2017 Jan;45(2):193-204.Full text Abstract
87. Giorli G, Rouette J, Yin H, et al. Prediagnostic use of low-dose aspirin and risk of incident metastasis and all-cause mortality among patients with colorectal cancer. Br J Clin Pharmacol. 2020 Nov;86(11):2266-73. Abstract
88. Nishihara R, Lochhead P, Kuchiba A, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013 Jun 26;309(24):2563-71.Full text Abstract
89. National Institute for Health and Care Excellence. Colorectal cancer. Dec 2021 [internet publication].Full text
90. Burn J, Sheth H, Elliott F, et al. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020 Jun 13;395(10240):1855-63.Full text Abstract
91. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: colorectal, endometrial, and gastric [internet publication].Full text
92. Tomić T, Domínguez-López S, Barrios-Rodríguez R. Non-aspirin non-steroidal anti-inflammatory drugs in prevention of colorectal cancer in people aged 40 or older: a systematic review and meta-analysis. Cancer Epidemiol. 2019 Feb;58:52-62. Abstract
93. Liang PS, Shaukat A, Crockett SD. AGA clinical practice update on chemoprevention for colorectal neoplasia: expert review. Clin Gastroenterol Hepatol. 2021 Jul;19(7):1327-36.Full text Abstract
94. Rostom A, Dubé C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007 Mar 6;146(5):376-89.Full text Abstract
95. Kim J, Boushey CJ, Wilkens LR, et al. Plant-based dietary patterns defined by a priori indices and colorectal cancer risk by sex and race/ethnicity: the multiethnic cohort study. BMC Med. 2022 Nov 29;20(1):430.Full text Abstract
96. Liu F, Lv Y, Peng Y, et al. Plant-based dietary patterns, genetic predisposition and risk of colorectal cancer: a prospective study from the UK Biobank. J Transl Med. 2023 Sep 27;21(1):669.Full text Abstract
97. Wang F, Ugai T, Haruki K, et al. Healthy and unhealthy plant-based diets in relation to the incidence of colorectal cancer overall and by molecular subtypes. Clin Transl Med. 2022 Aug;12(8):e893.Full text Abstract
98. Ben S, Du M, Ma G, et al. Vitamin B2 intake reduces the risk for colorectal cancer: a dose-response analysis. Eur J Nutr. 2019 Jun;58(4):1591-602. Abstract
99. Fu H, He J, Li C, et al. Folate intake and risk of colorectal cancer: a systematic review and up-to-date meta-analysis of prospective studies. Eur J Cancer Prev. 2023 Mar 1;32(2):103-12. Abstract
100. Aglago EK, Huybrechts I, Murphy N, et al. Consumption of fish and long-chain n-3 polyunsaturated fatty acids is associated with reduced risk of colorectal cancer in a large European cohort. Clin Gastroenterol Hepatol. 2020 Mar;18(3):654-66.e6.Full text Abstract
101. Li L, Wang D, He N, et al. Effects of polyunsaturated fatty acids on colorectal cancer patients: a meta-analysis of randomized controlled trials. Nutr Cancer. 2023;75(2):627-39.Full text Abstract
102. Cruz-Pierard SM, Nestares T, Amaro-Gahete FJ. Vitamin D and calcium as key potential factors related to colorectal cancer prevention and treatment: a systematic review. Nutrients. 2022 Nov 21;14(22):4934.Full text Abstract
103. Emami MH, Salehi M, Hassanzadeh Keshteli A, et al. Calcium and dairy products in the chemoprevention of colorectal adenomas: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2022;62(26):7168-83. Abstract
104. Lopez-Caleya JF, Ortega-Valín L, Fernández-Villa T, et al. The role of calcium and vitamin D dietary intake on risk of colorectal cancer: systematic review and meta-analysis of case-control studies. Cancer Causes Control. 2022 Feb;33(2):167-82. Abstract
105. Ma Y, You W, Cao Y, et al. Chemoprevention of colorectal cancer in general population and high-risk population: a systematic review and network meta-analysis. Chin Med J (Engl). 2023 Apr 5;136(7):788-98.Full text Abstract
106. Emmanouilidou G, Kalopitas G, Bakaloudi DR, et al. Vitamin D as a chemopreventive agent in colorectal neoplasms. a systematic review and meta-analysis of randomized controlled trials. Pharmacol Ther. 2022 Sep;237:108252. Abstract
107. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012 Feb 23;366(8):687-96.Full text Abstract
108. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017 Jun 6;112(7):1016-30.Full text Abstract
109. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. Aug 2023 [internet publication].Full text
110. Rockey DC, Cello JP. Evaluation of the gastrointestinal tract in patients with iron-deficiency anemia. N Engl J Med. 1993 Dec 2;329(23):1691-5.Full text Abstract
111. Raje D, Mukhtar H, Oshowo A, et al. What proportion of patients referred to secondary care with iron deficiency anemia have colon cancer? Dis Colon Rectum. 2007 Aug;50(8):1211-4. Abstract
112. Atkin W, Dadswell E, Wooldrage K, et al; SIGGAR Investigators. Computed tomographic colonography versus colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer (SIGGAR): a multicentre randomised trial. Lancet. 2013 Apr 6;381(9873):1194-202. Abstract
113. Vogel JD, Felder SI, Bhama AR, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colon cancer. Dis Colon Rectum. 2022 Feb 1;65(2):148-77.Full text Abstract
114. Bressler B, Paszat LF, Chen Z, et al. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology. 2007 Jan;132(1):96-102. Abstract
115. Lieberman DA, Weiss DG, Bond JH, et al; Veterans Affairs Cooperative Study Group 380. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. N Engl J Med. 2000 Jul 20;343(3):162-8.Full text Abstract
116. Luning T, Keemers-Gels M, Barendregt W, et al. Colonoscopic perforations: a review of 30,366 patients. Surg Endosc. 2007 Jun;21(6):994-7. Abstract
117. Holme Ø, Bretthauer M, Fretheim A, et al. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev. 2013 Oct 1;(9):CD009259.Full text Abstract
118. Zhang C, Liu L, Li J, et al. Effect of flexible sigmoidoscopy-based screening on colorectal cancer incidence and mortality: an updated systematic review and meta-analysis of randomized controlled trials. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(11):1217-27. Abstract
119. Gluecker TM, Johnson CD, Harmsen WS, et al. Colorectal cancer screening with CT colonography, colonoscopy, and double-contrast barium enema examination: prospective assessment of patient perceptions and preferences. Radiology. 2003 May;227(2):378-84. Abstract
120. Bosworth HB, Rockey DC, Paulson EK, et al. Prospective comparison of patient experience with colon imaging tests. Am J Med. 2006 Sep;119(9):791-9. Abstract
121. Halligan S, Wooldrage K, Dadswell E, et al; SIGGAR investigators. Computed tomographic colonography versus barium enema for diagnosis of colorectal cancer or large polyps in symptomatic patients (SIGGAR): a multicentre randomised trial. Lancet. 2013 Apr 6;381(9873):1185-93. Abstract
122. von Wagner C, Smith S, Halligan S, et al. Patient acceptability of CT colonography compared with double contrast barium enema: results from a multicentre randomised controlled trial of symptomatic patients. Eur Radiol. 2011 May 31;21(10):2046-55. Abstract
123. Rex DK, Rahmani EY, Haseman JH, et al. Relative sensitivity of colonoscopy and barium enema for detection of colorectal cancer in clinical practice. Gastroenterology. 1997 Jan;112(1):17-23. Abstract
124. Rockey RC, Paulson E, Niedzwiecki D, et al. Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison. Lancet. 2005 Jan 22-28;365(9456):305-11. Abstract
125. Mulhall BP, Veerappan GR, Jackson JL. Meta-analysis: computed tomographic colonography. Ann Intern Med. 2005 Apr 19;142(8):635-50.Full text Abstract
126. Glynne-Jones L, Wyrwicz E, Tiret G, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-40.Full text Abstract
127. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: rectal cancer [internet publication].Full text
128. Al-Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2012 Jul;19(7):2212-23. Abstract
129. Watson AJ, Lolohea S, Robertson GM, et al. The role of positron emission tomography in the management of recurrent colorectal cancer: a review. Dis Colon Rectum. 2007 Jan;50(1):102-14. Abstract
130. Zhang C, Chen Y, Xue H, et al. Diagnostic value of FDG-PET in recurrent colorectal carcinoma: a meta-analysis. Int J Cancer. 2009 Jan 1;124(1):167-73. Abstract
131. Facey K, Bradbury I, Laking G, et al. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess. 2007 Oct;11(44):iii-iv, xi-267.Full text Abstract
132. Moulton CA, Gu CS, Law CH, et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. JAMA. 2014 May 14;311(18):1863-9.Full text Abstract
133. Flamen P, Hoekstra OS, Homans F, et al. Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET). Eur J Cancer. 2001 May;37(7):862-9. Abstract
134. Royal College of Radiologists, Royal College of Physicians. Evidence-based indications for the use of PET-CT in the United Kingdom 2022 [internet publication].Full text
135. Yu T, Meng N, Chi D, et al. Diagnostic value of (18)F-FDG PET/CT in detecting local recurrent colorectal cancer: a pooled analysis of 26 individual studies. Cell Biochem Biophys. 2015 Jun;72(2):443-51. Abstract
136. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer [internet publication].Full text
137. National Institute for Health and Care Excellence. Colorectal cancer. Quality standard (QS20). Feb 2022 [internet publication].Full text
138. Lieberman DA, AGA CRC Workshop Panel. Commentary: liquid biopsy for average-risk colorectal cancer screening. Clin Gastroenterol Hepatol. 2024 Jun;22(6):1160-4.e1. Abstract
139. Chung DC, Gray DM 2nd, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med. 2024 Mar 14;390(11):973-83.Full text Abstract
140. Ladabaum U, Mannalithara A, Weng Y, et al. Comparative effectiveness and cost-effectiveness of colorectal cancer screening with blood-based biomarkers (liquid biopsy) vs fecal tests or colonoscopy. Gastroenterology. 2024 Jul;167(2):378-91. Abstract
141. van den Puttelaar R, Nascimento de Lima P, Knudsen AB, et al. Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening With a Blood Test That Meets the Centers for Medicare & Medicaid Services coverage decision. Gastroenterology. 2024 Jul;167(2):368-77.Full text Abstract
142. Burke CA, Lieberman D, Feuerstein JD. AGA Clinical practice update on approach to the use of noninvasive colorectal cancer screening options: commentary. Gastroenterology. 2022 Mar;162(3):952-6.Full text Abstract
143. du Toit J, Hamilton W, Barraclough K. Risk in primary care of colorectal cancer from new onset rectal bleeding: 10 year prospective study. BMJ. 2006 Jul 8;333(7558):69-70. Abstract
144. McSherry CK, Cornell GN, Glenn F. Carcinoma of the colon and rectum. Ann Surg. 1969 Apr;169(4):502-9. Abstract
145. Shallow TA, Wagner FB, Colcher RE. Clinical evaluation of 750 patients with colon cancer. Diagnostic survey and follow up covering a 15 year period. Ann Surg. 1955 Aug;142(2):164-75. Abstract
146. Holtedahl K, Borgquist L, Donker GA, et al. Symptoms and signs of colorectal cancer, with differences between proximal and distal colon cancer: a prospective cohort study of diagnostic accuracy in primary care. BMC Fam Pract. 2021 Jul 8;22(1):148.Full text Abstract
147. Kanellos D, Kitsios G, Kanellos I, et al. Anemia as a symptom of right colon cancer. Tech Coloproctol. 2004 Nov;8 Suppl 1:s62-4. Abstract
148. Maas MHJ, Neumann H, Shirin H, et al. A computer-aided polyp detection system in screening and surveillance colonoscopy: an international, multicentre, randomised, tandem trial. Lancet Digit Health. 2024 Mar;6(3):e157-65.Full text Abstract
149. Hassan C, Spadaccini M, Mori Y, et al. Real-time computer-aided detection of colorectal neoplasia during colonoscopy: a systematic review and meta-analysis. Ann Intern Med. 2023 Sep;176(9):1209-20. Abstract
150. Thoeni RF. Colorectal cancer. Radiologic staging. Radiol Clin North Am. 1997 Mar;35(2):457-85. Abstract
151. Scott AJ, Kennedy EB, Berlin J, et al. Management of locally advanced rectal cancer: ASCO guideline. J Clin Oncol. 2024 Oct;42(28):3355-75.Full text Abstract
152. Kwok H, Bissett IP, Hill GL. Preoperative staging of rectal cancer. Int J Colorectal Dis. 2000 Feb;15(1):9-20. Abstract
153. Nikolaou S, Qiu S, Fiorentino F, et al. Systematic review of blood diagnostic markers in colorectal cancer. Tech Coloproctol. 2018 Jul 18;22(7):481-98.Full text Abstract
154. Nicholson BD, Shinkins B, Pathiraja I, et al. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev. 2015 Dec 10;(12):CD011134.Full text Abstract
155. Shinkins B, Nicholson BD, James T, et al. What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial. Health Technol Assess. 2017 Apr;21(22):1-60.Full text Abstract
156. Backes Y, Moss A, Reitsma JB, et al. Narrow band imaging, magnifying chromoendoscopy, and gross morphological features for the optical diagnosis of T1 colorectal cancer and deep submucosal invasion: a systematic review and meta-analysis. Am J Gastroenterol. 2016 Sep 20;112(1):54-64. Abstract
157. Fan X, Zhang J, Lu D. CtDNA's prognostic value in patients with early-stage colorectal cancer after surgery: a meta-analysis and systematic review. Medicine (Baltimore). 2023 Feb 10;102(6):e32939.Full text Abstract
158. Faulkner LG, Howells LM, Pepper C, et al. The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis. Br J Cancer. 2023 Jan;128(2):297-309.Full text Abstract
159. Mi J, Wang R, Han X, et al. Treatment stratification and prognosis assessment using circulating tumor DNA in locally advanced rectal cancer: a systematic review and meta-analysis. Cancer Med. 2023 Sep;12(17):17934-44.Full text Abstract
160. Wullaert L, van Rees JM, Martens JWM, et al. Circulating tumour DNA as biomarker for colorectal liver metastases: a systematic review and meta-analysis. Cells. 2023 Oct 25;12(21):2520.Full text Abstract
161. Loft M, To YH, Gibbs P, et al. Clinical application of circulating tumour DNA in colorectal cancer. Lancet Gastroenterol Hepatol. 2023 Sep;8(9):837-52. Abstract
162. Dawood ZS, Alaimo L, Lima HA, et al. Circulating tumor DNA, imaging, and carcinoembryonic antigen: comparison of surveillance strategies among patients who underwent resection of colorectal cancer-a systematic review and meta-analysis. Ann Surg Oncol. 2023 Jan;30(1):259-74. Abstract
163. Chidharla A, Rapoport E, Agarwal K, et al. Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in patients undergoing curative-intent resection with or without adjuvant chemotherapy in colorectal cancer: a systematic review and meta-analysis. Int J Mol Sci. 2023 Jun 16;24(12):10230.Full text Abstract
164. Bratman SV, Yang SYC, Iafolla MAJ, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020 Sep;1(9):873-81. Abstract
165. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016 May;150(6):1393-407. Abstract
166. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002 Dec;123(6):2108-31.Full text Abstract
167. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011 May;140(6):1785-94.Full text Abstract
168. Shergill AK, Lightdale JR, Bruining DH, et al; American Society for Gastrointestinal Endoscopy Standards of Practice Committee. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015 Mar 20;81(5):1101-21.e1-13.Full text Abstract
169. US Preventive Services Task Force., Davidson KW, Barry MJ, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021 May 18;325(19):1965-77.Full text Abstract
170. Lieberman D, Ladabaum U, Brill JV, et al. Reducing the burden of colorectal cancer: AGA position statements. Gastroenterology. 2022 Aug;163(2):520-6.Full text Abstract
171. Patel SG, May FP, Anderson JC, et al. Updates on age to start and stop colorectal cancer screening: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2022 Jan 1;117(1):57-69.Full text Abstract
172. Wolf AM, Fontham ET, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018 May 30;68(4):250-81.Full text Abstract
173. Qaseem A, Harrod CS, Crandall CJ, et al. Screening for colorectal cancer in asymptomatic average-risk adults: a guidance statement from the American College of Physicians (version 2). Ann Intern Med. 2023 Aug;176(8):1092-100.Full text Abstract
174. NEJM Journal Watch. The American College of Physicians weighs in on colorectal cancer screening. Aug 2023 [internet publication].
175. Canadian Task Force on Preventive Health Care. Recommendations on screening for colorectal cancer in primary care. CMAJ. 2016 Mar 15;188(5):340-8.Full text Abstract
176. Buskermolen M, Cenin DR, Helsingen LM, et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. BMJ. 2019 Oct 2;367:l5383.Full text Abstract
177. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015 Feb 3;110(2):223-62.Full text Abstract
178. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Dis Colon Rectum. 2014 Aug;57(8):1025-48. Abstract
179. Boland CR, Idos GE, Durno C, et al. Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis syndromes: recommendations from the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2022 Jun 1;117(6):846-64.Full text Abstract
180. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019 Mar;114(3):384-413.Full text Abstract
181. Murthy SK, Feuerstein JD, Nguyen GC, et al. AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review. Gastroenterology. 2021 Sep;161(3):1043-51.e4.Full text Abstract
182. Cairns SR, Scholefield JH, Steele RJ, et al; British Society of Gastroenterology; Association of Coloproctology for Great Britain and Ireland. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010 May;59(5):666-89. Abstract
183. American College of Radiology. ACR appropriateness criteria: colorectal cancer screening. 2024 [internet publication].Full text
184. Langenfeld SJ, Davis BR, Vogel JD, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer 2023 Supplement. Dis Colon Rectum. 2024 Jan 1;67(1):18-31.Full text Abstract
185. American College of Radiology. ACR Appropriateness Criteria: staging of colorectal cancer. 2021 [internet publication].Full text
186. van Gijn W, Gooiker GA, Wouters MW, et al. Volume and outcome in colorectal cancer surgery. Eur J Surg Oncol. 2010;36(suppl 1):S55-S63. Abstract
187. Molenaar CJ, van Rooijen SJ, Fokkenrood HJ, et al. Prehabilitation versus no prehabilitation to improve functional capacity, reduce postoperative complications and improve quality of life in colorectal cancer surgery. Cochrane Database Syst Rev. 2022 May 19;5(5):CD013259.Full text Abstract
188. Molenaar CJL, Minnella EM, Coca-Martinez M, et al. Effect of multimodal prehabilitation on reducing postoperative complications and enhancing functional capacity following colorectal cancer surgery: the PREHAB randomized clinical trial. JAMA Surg. 2023 Jun 1;158(6):572-81.Full text Abstract
189. Cheng H, Zhou M, Yang L, et al. The impact of laparoscopic, open, extended right, and left colectomy on clinical outcomes of splenic flexure colon cancer: a meta-analysis. Medicine (Baltimore). 2023 May 12;102(19):e33742.Full text Abstract
190. Kampman SL, Smalbroek BP, Dijksman LM, et al. Postoperative inflammatory response in colorectal cancer surgery: a meta-analysis. Int J Colorectal Dis. 2023 Sep 19;38(1):233. Abstract
191. Nelson H, Sargent DJ, Wieand HS, et al; Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004 May 13;350(20):2050-9.Full text Abstract
192. Buunen M, Veldkamp R, Hop WC, et al; Colon Cancer Laparoscopic or Open Resection Study Group. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial. Lancet Oncol. 2009 Jan;10(1):44-52. Abstract
193. Green BL, Marshall HC, Collinson F, et al. Long-term follow-up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. Br J Surg. 2013 Jan;100(1):75-82.Full text Abstract
194. Kennedy RH, Francis EA, Wharton R, et al. Multicenter randomized controlled trial of conventional versus laparoscopic surgery for colorectal cancer within an enhanced recovery programme: EnROL. J Clin Oncol. 2014 Jun 10;32(17):1804-11.Full text Abstract
195. Cui M, Liu S. Meta-analysis of the effect of laparoscopic surgery and open surgery on long-term quality of life in patients with colorectal cancer. Medicine (Baltimore). 2023 Sep 8;102(36):e34922.Full text Abstract
196. Lai JH, Law WL. Laparoscopic surgery for colorectal cancer. Br Med Bull. 2012 Oct 19;104:61-89.Full text Abstract
197. Anderson C, Uman G, Pigazzi A. Oncologic outcomes of laparoscopic surgery for rectal cancer: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008 Oct;34(10):1135-42. Abstract
198. Ng SS, Lee JF, Yiu RY, et al. Long-term oncologic outcomes of laparoscopic versus open surgery for rectal cancer: a pooled analysis of 3 randomized controlled trials. Ann Surg. 2014 Jan;259(1):139-47. Abstract
199. Vennix S, Pelzers L, Bouvy N, et al. Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database Syst Rev. 2014 Apr 15;(4):CD005200.Full text Abstract
200. Bonjer HJ, Deijen CL, Abis GA, et al; COLOR II Study Group. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med. 2015 Apr 2;372(14):1324-32.Full text Abstract
201. Jeong SY, Park JW, Nam BH, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol. 2014 Jun;15(7):767-74. Abstract
202. Fleshman J, Branda M, Sargent DJ, et al. Effect of laparoscopic-assisted resection vs. open resection of stage II or III rectal cancer on pathologic outcomes: the ACOSOG Z6051 randomized clinical trial. JAMA. 2015 Oct 6;314(13):1346-55. Abstract
203. Prete FP, Pezzolla A, Prete F, et al. Robotic versus laparoscopic minimally invasive surgery for rectal cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Surg. 2018 Jun;267(6):1034-46. Abstract
204. Holmer C, Kreis ME. Systematic review of robotic low anterior resection for rectal cancer. Surg Endosc. 2017 Dec 7;32(2):569-81. Abstract
205. Lee SH, Kim DH, Lim SW. Robotic versus laparoscopic intersphincteric resection for low rectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis. 2018 Sep 5;33(12):1741-53. Abstract
206. Martins RS, Fatimi AS, Mahmud O, et al. Multidimensional quality of life after robotic versus laparoscopic surgery for rectal cancer: a systematic review and meta-analysis. World J Surg. 2023 May;47(5):1310-9. Abstract
207. Seow W, Dudi-Venkata NN, Bedrikovetski S, et al. Outcomes of open vs laparoscopic vs robotic vs transanal total mesorectal excision (TME) for rectal cancer: a network meta-analysis. Tech Coloproctol. 2023 May;27(5):345-60. Abstract
208. Li X, Liu ZH, Wang N, et al. Robotic versus laparoscopic total mesorectal excision for rectal cancer: a meta-analysis of long-term survival and urogenital functional outcomes. Minerva Gastroenterol (Torino). 2023 Sep;69(3):403-11. Abstract
209. Jayne D, Pigazzi A, Marshall H, et al. Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA. 2017 Oct 24;318(16):1569-80. Abstract
210. Spanjersberg WR, Reurings J, Keus F, et al. Fast track surgery versus conventional recovery strategies for colorectal surgery. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD007635.Full text Abstract
211. van der Pas MH, Haglind E, Cuesta MA, et al. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. Lancet Oncol. 2013 Mar;14(3):210-8. Abstract
212. Li N, Liu Y, Chen H, et al. Efficacy and safety of enhanced recovery after surgery pathway in minimally invasive colorectal cancer surgery: a systemic review and meta-analysis. J Laparoendosc Adv Surg Tech A. 2023 Feb;33(2):177-87. Abstract
213. Sajid MS, Farag S, Leung P, et al. Systematic review and meta-analysis of published trials comparing the effectiveness of transanal endoscopic microsurgery and radical resection in the management of early rectal cancer. Colorectal Dis. 2014 Jan;16(1):2-14. Abstract
214. Sgourakis G, Lanitis S, Gockel I, et al. Transanal endoscopic microsurgery for T1 and T2 rectal cancers: a meta-analysis and meta-regression analysis of outcomes. Am Surg. 2011 Jun;77(6):761-72. Abstract
215. Clancy C, Burke JP, Albert MR, et al. Transanal endoscopic microsurgery versus standard transanal excision for the removal of rectal neoplasms: a systematic review and meta-analysis. Dis Colon Rectum. 2015 Feb;58(2):254-61. Abstract
216. Kim M, Bareket R, Eleftheriadis NP, et al. Endoscopic submucosal dissection (ESD) offers a safer and more cost-effective alternative to transanal endoscopic microsurgery (TEM): an international collaborative study. J Clin Gastroenterol. 2023 May-Jun 01;57(5):486-9. Abstract
217. Kiriyama S, Saito Y, Matsuda T, et al. Comparing endoscopic submucosal dissection with transanal resection for non-invasive rectal tumor: a retrospective study. J Gastroenterol Hepatol. 2011 Jun;26(6):1028-33. Abstract
218. Park SU, Min YW, Shin JU, et al. Endoscopic submucosal dissection or transanal endoscopic microsurgery for nonpolypoid rectal high grade dysplasia and submucosa-invading rectal cancer. Endoscopy. 2012 Nov;44(11):1031-6. Abstract
219. Bax TW, McNevin MS. The value of diverting loop ileostomy on the high-risk colon and rectal anastomosis. Am J Surg. 2007 May;193(5):585-7; discussion 587-8. Abstract
220. Hanna MH, Vinci A, Pigazzi A. Diverting ileostomy in colorectal surgery: when is it necessary? Langenbecks Arch Surg. 2015 Feb;400(2):145-52. Abstract
221. Lynn PB, Renfro LA, Carrero XW, et al. Anorectal function and quality of life in patients with early stage rectal cancer treated with chemoradiation and local excision. Dis Colon Rectum. 2017 May;60(5):459-68. Abstract
222. Rödel C, Liersch T, Becker H, et al; German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012 Jul;13(7):679-87. Abstract
223. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012 Jun 1;30(16):1926-33. Abstract
224. Fiorica F, Cartei F, Licata A, et al. Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data. Cancer Treat Rev. 2010 Nov;36(7):539-49. Abstract
225. Tiv M, Puyraveau M, Mineur L, et al. Long-term quality of life in patients with rectal cancer treated with preoperative (chemo)-radiotherapy within a randomized trial. Cancer Radiother. 2010 Oct;14(6-7):530-4. Abstract
226. Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021 May;22(5):702-15. Abstract
227. van Gijn W, Marijnen CA, Nagtegaal ID, et al; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011 Jun;12(6):575-82. Abstract
228. Pettersson D, Cedermark B, Holm T, et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg. 2010 Apr;97(4):580-7. Abstract
229. Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012 Nov 1;30(31):3827-33. Abstract
230. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol. 2004 Jul;72(1):15-24. Abstract
231. Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):29-42. Abstract
232. Dijkstra EA, Nilsson PJ, Hospers GAP, et al. Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-Year follow-up of the RAPIDO trial. Ann Surg. 2023 Oct 1;278(4):e766-72.Full text Abstract
233. ClinicalTrials.gov. Short RT versus RCT,followed by chemo.and organ preservation for interm and high-risk rectal cancer patients. ClinicalTrials.gov Identifier: NCT04246684. Sep 2019 [internet publication].Full text
234. van den Broek CB, Vermeer TA, Bastiaannet E, et al. Impact of the interval between short-course radiotherapy and surgery on outcomes of rectal cancer patients. Eur J Cancer. 2013 Oct;49(15):3131-9.Full text Abstract
235. Erlandsson J, Holm T, Pettersson D, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017 Mar;18(3):336-46. Abstract
236. Wo JY, Ashman JB, Bhadkamkar NA, et al. Radiation therapy for rectal cancer: an ASTRO clinical practice guideline focused update. Pract Radiat Oncol. 25 Nov 2024 [Epub ahead of print].Full text Abstract
237. Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol. 2010 Sep;21(9):1743-50.Full text Abstract
238. Bosset JF, Calais G, Mineur L, et al; EORTC Radiation Oncology Group. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014 Feb;15(2):184-90. Abstract
239. Cancer Care Ontario. Preoperative or postoperative therapy for the management of patients with stage II or III rectal cancer. Mar 2019 [internet publication].Full text
240. Hong YS, Kim SY, Lee JS, et al. Oxaliplatin-based adjuvant chemotherapy for rectal cancer after preoperative chemoradiotherapy (ADORE): long-term results of a randomized controlled trial. J Clin Oncol. 2019 Nov 20;37(33):3111-23.Full text Abstract
241. Kim TW, Lee JH, Lee JH, et al. Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1025-31. Abstract
242. Zhang X, Ma S, Guo Y, et al. Total neoadjuvant therapy versus standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis of 15 trials. PLoS One. 2022;17(11):e0276599.Full text Abstract
243. Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018 Jun 14;4(6):e180071.Full text Abstract
244. de Mestier L, Manceau G, Neuzillet C, et al. Primary tumor resection in colorectal cancer with unresectable synchronous metastases: a review. World J Gastrointest Oncol. 2014 Jun 15;6(6):156-69.Full text Abstract
245. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002 Jun;235(6):759-66.Full text Abstract
246. Cummings LC, Payes JD, Cooper GS. Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer. 2007 Feb 15;109(4):718-26.Full text Abstract
247. Cao G, Cheng D, Ye L, et al. Surgical resection of pulmonary metastases from colorectal cancer: 11 years of experiences. PLoS One. 2017 Apr 10;12(4):e0175284.Full text Abstract
248. Groot Koerkamp B, Sadot E, Kemeny NE, et al. Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis. J Clin Oncol. 2017 Jun 10;35(17):1938-44.Full text Abstract
249. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004 Jun;15(6):933-9.Full text Abstract
250. Ozair A, Collings A, Adams AM, et al. Minimally invasive versus open hepatectomy for the resection of colorectal liver metastases: a systematic review and meta-analysis. Surg Endosc. 2022 Nov;36(11):7915-37. Abstract
251. Vreeland TJ, Collings AT, Ozair A, et al. SAGES/AHPBA guidelines for the use of minimally invasive surgery for the surgical treatment of colorectal liver metastases (CRLM). Surg Endosc. 2023 Apr;37(4):2508-16. Abstract
252. Petrelli F, Comito T, Barni S, et al. Stereotactic body radiotherapy for colorectal cancer liver metastases: A systematic review. Radiother Oncol. 2018 Dec;129(3):427-34. Abstract
253. Abdalla M, Collings AT, Dirks R, et al. Surgical approach to microwave and radiofrequency liver ablation for hepatocellular carcinoma and colorectal liver metastases less than 5 cm: a systematic review and meta-analysis. Surg Endosc. 2023 May;37(5):3340-53. Abstract
254. Ceppa EP, Collings AT, Abdalla M, et al. SAGES/AHPBA guidelines for the use of microwave and radiofrequency liver ablation for the surgical treatment of hepatocellular carcinoma or colorectal liver metastases less than 5 cm. Surg Endosc. 2023 Dec;37(12):8991-9000. Abstract
255. Hall B, Padussis J, Foster JM. Cytoreduction and hyperthermic intraperitoneal chemotherapy in the management of colorectal peritoneal metastasis. Surg Clin North Am. 2017 Jun;97(3):671-82. Abstract
256. Baratti D, Kusamura S, Pietrantonio F, et al. Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review. Crit Rev Oncol Hematol. 2016 Jan 22;100:209-22. Abstract
257. Haram A, Boland MR, Kelly ME, et al. The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review. J Surg Oncol. 2017 Jan 20;115(4):470-9. Abstract
258. Min GT, Wang YH, Yao N, et al. The prognostic role of pretreatment platelet-to-lymphocyte ratio as predictors in patients with colorectal cancer: a meta-analysis. Biomark Med. 2016 Dec 5;11(1):87-97. Abstract
259. Tan D, Fu Y, Su Q, et al. Prognostic role of platelet-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Medicine (Baltimore). 2016 Jun;95(24):e3837.Full text Abstract
260. Tsai PL, Su WJ, Leung WH, et al. Neutrophil-lymphocyte ratio and CEA level as prognostic and predictive factors in colorectal cancer: a systematic review and meta-analysis. J Cancer Res Ther. 2016 Apr-Jun;12(2):582-9.Full text Abstract
261. Colloca G, Venturino A, Guarneri D. Neutrophil-to-lymphocyte ratio predicts survival of patients with rectal cancer receiving neo-adjuvant chemoradiation followed by radical resection: a meta-analysis. Expert Rev Anticancer Ther. 2023 Apr;23(4):421-9. Abstract
262. Portale G, Bartolotta P, Azzolina D, et al. Prognostic role of platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte, and lymphocyte-to-monocyte ratio in operated rectal cancer patients: systematic review and meta-analysis. Langenbecks Arch Surg. 2023 Feb 13;408(1):85. Abstract
263. Lin N, Li J, Yao X, et al. Prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer liver metastasis: a meta-analysis of results from multivariate analysis. Int J Surg. 2022 Nov;107:106959.Full text Abstract
264. Zhu L, Dong C, Cao Y, et al. Prognostic role of BRAF mutation in stage II/III colorectal cancer receiving curative resection and adjuvant chemotherapy: a meta-analysis based on randomized clinical trials. PLoS One. 2016 May 3;11(5):e0154795.Full text Abstract
265. Pikoulis E, Margonis GA, Andreatos N, et al. Prognostic role of BRAF mutations in colorectal cancer liver metastases. Anticancer Res. 2016 Sep;36(9):4805-11.Full text Abstract
266. Li ZN, Zhao L, Yu LF, et al. BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterol Rep (Oxf). 2020 Jun;8(3):192-205.Full text Abstract
267. Costas-Chavarri A, Nandakumar G, Temin S, et al. Treatment of patients with early-stage colorectal cancer: ASCO resource-stratified guideline. J Glob Oncol. 2019 Feb;5:1-19.Full text Abstract
268. Maak M, Simon I, Nitsche U, et al. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Ann Surg. 2013 Jun;257(6):1053-8. Abstract
269. Venook AP, Niedzwiecki D, Lopatin M, et al. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol. 2013 May 10;31(14):1775-81.Full text Abstract
270. Kim HS, Noh GT, Chung SS, et al. Long-term oncological outcomes of robotic versus laparoscopic approaches for right colon cancer: a systematic review and meta-analysis. Tech Coloproctol. 2023 Dec;27(12):1183-9. Abstract
271. Meyers BM, Cosby R, Quereshy F, et al. Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline. Curr Oncol. 2016 Dec 21;23(6):418-24.Full text Abstract
272. Lieu C, Kennedy EB, Bergsland E, et al. Duration of oxaliplatin-containing adjuvant therapy for stage III colon cancer: ASCO clinical practice guideline. J Clin Oncol. 2019 Jun 1;37(16):1436-47.Full text Abstract
273. Kim ST, Kim SY, Lee J, et al. Oxaliplatin (3 months v 6 months) with 6 months of fluoropyrimidine as adjuvant therapy in patients with stage II/III colon cancer: KCSG CO09-07. J Clin Oncol. 2022 Nov 20;40(33):3868-77.Full text Abstract
274. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009 Jul 1;27(19):3109-16.Full text Abstract
275. Baxter NN, Kennedy EB, Bergsland E, et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J Clin Oncol. 2022 Mar 10;40(8):892-910.Full text Abstract
276. André T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015 Dec 10;33(35):4176-87. Abstract
277. Chibaudel B, Raeisi M, Cohen R, et al. Assessment of the addition of oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy in patients with high-risk stage II colon cancer: an ACCENT pooled analysis. J Clin Oncol. 2024 Dec 10;42(35):4187-95. Abstract
278. Loree JM, Sha A, Soleimani M, et al. Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer. Clin Colorectal Cancer. 2018 Feb 7;17(2):156-63. Abstract
279. Tournigand C, André T, Bonnetain F, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol. 2012 Sep 20;30(27):3353-60. Abstract
280. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010 Jul 10;28(20):3219-26.Full text Abstract
281. Des Guetz G, Nicolas P, Perret GY, et al. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer. 2010 Apr;46(6):1049-55. Abstract
282. Biagi JJ, Raphael MJ, Mackillop WJ, et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer. JAMA. 2011 Jun 8;305(22):2335-42. Abstract
283. Pikouli A, Papaconstantinou D, Wang J, et al. Reevaluating the prognostic role of BRAF mutation in colorectal cancer liver metastases. Am J Surg. 2022 May;223(5):879-83. Abstract
284. Lopez NE, Weiss AC, Robles J, et al. A systematic review of clinically available gene expression profiling assays for stage II colorectal cancer: initial steps toward genetic staging. Am J Surg. 2016 Aug 1;212(4):700-14. Abstract
285. Morton D, Seymour M, Magill L, et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol. 2023 Mar 10;41(8):1541-52.Full text Abstract
286. Clark ME, Smith RR. Liver-directed therapies in metastatic colorectal cancer. J Gastrointest Oncol. 2014 Oct;5(5):374-87.Full text Abstract
287. De Groote K, Prenen H. Intrahepatic therapy for liver-dominant metastatic colorectal cancer. World J Gastrointest Oncol. 2015 Sep 15;7(9):148-52.Full text Abstract
288. Jones C, Badger SA, Ellis G. The role of microwave ablation in the management of hepatic colorectal metastases. Surgeon. 2011 Feb;9(1):33-7. Abstract
289. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008 Feb 1;26(4):689-90. Abstract
290. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol. 2006 Jan 20;24(3):394-400.Full text Abstract
291. Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 2017 Jun 20;317(23):2392-401.Full text Abstract
292. Chiorean EG, Nandakumar G, Fadelu T, et al. Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline. JCO Glob Oncol. 2020 Mar;6:414-38.Full text Abstract
293. Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008 Apr 20;26(12):2006-12.Full text Abstract
294. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol. 2008 Oct;19(10):1720-6.Full text Abstract
295. Marques RP, Duarte GS, Sterrantino C, et al. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Aug 25;118:54-62. Abstract
296. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007 Oct 20;25(30):4779-86.Full text Abstract
297. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008 Apr 20;26(12):2013-9. Abstract
298. Giantonio BJ, Catalano PJ, Meropol NJ, et al; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007 Apr 20;25(12):1539-44. Abstract
299. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013 Jan;14(1):29-37. Abstract
300. Botrel TE, Clark LG, Paladini L, et al. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2016 Aug 24;16:677.Full text Abstract
301. Pei X, Liu Y, Sun L, et al. Outcome of molecular targeted agents plus chemotherapy for second-line therapy of metastatic colorectal cancer: a meta-analysis of randomized trials. Clin Colorectal Cancer. 2016 Mar 31;15(4):e149-56. Abstract
302. Cremolini C, Antoniotti C, Stein A, et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020 Aug 20;JCO2001225. Abstract
303. Tang W, Ren L, Liu T, et al. Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: the BECOME randomized controlled trial. J Clin Oncol. 2020 Sep 20;38(27):3175-84.Full text Abstract
304. Zhu X, Tian X, Yu C, et al. Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: an updated meta-analysis of 12 randomized controlled trials. Medicine (Baltimore). 2016 Aug;95(34):e4232.Full text Abstract
305. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012 Oct 1;30(28):3499-506. Abstract
306. Tabernero J, Yoshino T, Cohn AL, et al; RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 May;16(5):499-508. Abstract
307. Chen Q, Cheng M, Wang Z, et al. The efficacy and safety of panitumumab plus irinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis. Medicine (Baltimore). 2016 Dec;95(50):e5284.Full text Abstract
308. Heinemann V, Rivera F, O'Neil BH, et al. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. Eur J Cancer. 2016 Sep 1;67:11-20.Full text Abstract
309. Yang YF, Wang GY, He JL, et al. Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: a meta-analysis. Medicine (Baltimore). 2017 Mar;96(12):e6335.Full text Abstract
310. Wang Y, Li X, Huang T, et al. The efficacy and safety of anti-EGFR target agents in patients with potentially resectable metastatic colorectal cancer: a meta-analysis of randomized controlled trials. World J Surg Oncol. 2023 Oct 26;21(1):340.Full text Abstract
311. Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2017 Feb 6;141(5):625-57.Full text Abstract
312. Pietrantonio F, Cremolini C, Petrelli F, et al. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2015 Jun 5;96(1):156-66. Abstract
313. Modest DP, Karthaus M, Fruehauf S, et al. Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer: The randomized PANAMA trial (AIO KRK 0212). J Clin Oncol. 2021 Sep 17;JCO2101332.Full text Abstract
314. Watanabe J, Muro K, Shitara K, et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA. 2023 Apr 18;329(15):1271-82.Full text Abstract
315. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014 Oct 23;371(17):1609-18.Full text Abstract
316. Hochster HS, Grothey A, Hart L, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol. 2014 Jun;25(6):1172-8.Full text Abstract
317. Yalcin S, Uslu R, Dane F, et al. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results - a Turkish Oncology Group Trial. Oncology. 2013;85(6):328-35.Full text Abstract
318. Simkens LH, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015 May 9;385(9980):1843-52. Abstract
319. Aparicio T, Ghiringhelli F, Boige V, et al. Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9). J Clin Oncol. 2018 Mar 1;36(7):674-81. Abstract
320. Adams RA, Fisher DJ, Graham J, et al. Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the randomized FOCUS4-N trial. J Clin Oncol. 2021 Sep 13;JCO2101436.Full text Abstract
321. Ma H, Wu X, Tao M, et al. Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: a meta-analysis. Medicine (Baltimore). 2019 Dec;98(50):e18227.Full text Abstract
322. Xu W, Gong Y, Kuang M, et al. Survival benefit and safety of bevacizumab in combination with erlotinib as maintenance therapy in patients with metastatic colorectal cancer: a meta-analysis. Clin Drug Investig. 2017 Feb;37(2):155-65. Abstract
323. Lo Nigro C, Ricci V, Vivenza D, et al. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World J Gastroenterol. 2016 Aug 14;22(30):6944-54.Full text Abstract
324. Grothey A, Van Cutsem E, Sobrero A, et al; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):303-12. Abstract
325. Mercier J, Voutsadakis IA. A systematic review and meta-analysis of retrospective series of regorafenib for treatment of metastatic colorectal cancer. Anticancer Res. 2017 Nov;37(11):5925-34.Full text Abstract
326. Røed Skårderud M, Polk A, Kjeldgaard Vistisen K, et al. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a systematic review. Cancer Treat Rev. 2017 Nov 10;62:61-73. Abstract
327. Mayer RJ, Van Cutsem E, Falcone A, et al; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015 May 14;372(20):1909-19.Full text Abstract
328. Prager GW, Taieb J, Fakih M, et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023 May 4;388(18):1657-67.Full text Abstract
329. Voutsadakis IA. A systematic review and meta-analysis of trifluridine/tipiracil plus bevacizumab for the treatment of metastatic colorectal cancer: evidence from real-world series. Curr Oncol. 2023 May 24;30(6):5227-39.Full text Abstract
330. Li J, Qin S, Xu RH, et al. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 2018 Jun 26;319(24):2486-96.Full text Abstract
331. ClinicalTrials.gov. A study of efficacy and safety of fruquintinib (HMPL-013) in patients with metastatic colorectal cancer (FRESCO-2). Mar 2023 [internet publication].Full text
332. Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 Jul 1;402(10395):41-53. Abstract
333. André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020 Dec 3;383(23):2207-18. Abstract
334. Andre T, Amonkar M, Norquist JM, et al. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 May;22(5):665-77. Abstract
335. Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022 May;23(5):659-70. Abstract
336. Overman MJ, Lonardi S, Wong KY, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018 Jan 20;36(8):773-9.Full text Abstract
337. ClinicalTrials.gov. Study of induction PD-1 blockade in subjects with locally advanced mismatch repair deficient solid tumors. Oct 2022 [internet publication].Full text
338. Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022 Jun 23;386(25):2363-76. Abstract
339. Zhou X, Yao Z, Bai H, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol. 2021 Sep;22(9):1265-74. Abstract
340. National Institute for Health and Care Excellence. Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer. Jan 2021 [internet publication].Full text
341. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019 Oct 24;381(17):1632-43.Full text Abstract
342. Yaeger R, Weiss J, Pelster MS, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023 Jan 5;388(1):44-54.Full text Abstract
343. Kuboki Y, Fakih M, Strickler J, et al. Sotorasib with panitumumab in chemotherapy-refractory KRAS(G12C)-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan;30(1):265-70. Abstract
344. Fakih MG, Salvatore L, Esaki T, et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023 Dec 7;389(23):2125-39.Full text Abstract
345. Yaeger R, Uboha NV, Pelster MS, et al. Efficacy and safety of adagrasib plus cetuximab in patients with KRASG12C-mutated metastatic colorectal cancer. Cancer Discov. 2024 Jun 3;14(6):982-93.Full text Abstract
346. ClinicalTrials.gov. Phase 1/2 Study of MRTX849 in patients with cancer having a KRAS G12C mutation KRYSTAL-1. ClinicalTrials.gov Identifier: NCT03785249. Sep 2024 [internet publication].Full text
347. Raghav K, Siena S, Takashima A, et al. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol. 2024 Sep;25(9):1147-62. Abstract
348. Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023 May;24(5):496-508. Abstract
349. Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-73.Full text Abstract
350. Drilon A, Subbiah V, Gautschi O, et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol. 2023 Jan 10;41(2):385-94.Full text Abstract
351. Mocellin S, Baretta Z, Roqué I, et al. Second-line systemic therapy for metastatic colorectal cancer. Cochrane Database Syst Rev. 2017 Jan 27;(1):CD006875.Full text Abstract
352. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008 May 10;26(14):2311-9. Abstract
353. Aldrich J, Pundole X, Tummala S, et al. Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors. Arthritis Rheumatol. 2021 May;73(5):866-74. Abstract
354. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005 Oct 1;23(28):7125-34.Full text Abstract
355. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013 Sep 12;369(11):1023-34.Full text Abstract
356. Van Cutsem E, Lenz HJ, Köhne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015 Mar 1;33(7):692-700.Full text Abstract
357. ClinicalTrials.gov. SOX versus XELOX as adjuvant chemotherapy for stage III colorectal cancer patients. ClinicalTrials.gov identifier: NCT03448549. Mar 2020 [internet publication].Full text
358. ClinicalTrials.gov. A study of botensilimab and balstilimab for the treatment of colorectal cancer. Apr 2023 [internet publication].Full text
359. Huang W, Sundquist J, Sundquist K, et al. Use of phosphodiesterase 5 inhibitors is associated with lower risk of colorectal cancer in men with benign colorectal neoplasms. Gastroenterology. 2019 Sep;157(3):672-81.e4.Full text Abstract
360. Cullinane C, Brett A, Devane L, et al. The protective role of phosphodiesterase inhibitors in preventing colorectal cancer and advanced colorectal polyps: a systematic review and meta-analysis. Colorectal Dis. 2023 Oct;25(10):1949-59. Abstract
361. Huang W, Sundquist J, Sundquist K, et al. Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer. Nat Commun. 2020 Jun 24;11(1):3191.Full text Abstract
362. Bjørn MX, Perdawood SK. Transanal total mesorectal excision--a systematic review. Dan Med J. 2015 Jul;62(7):A5105.Full text Abstract
363. Lau SYC, Choy KT, Yang TWW, et al. Defining the learning curve of transanal total mesorectal excision: a systematic review and meta-analysis. ANZ J Surg. 2022 Mar;92(3):355-64. Abstract
364. Butterworth JW, Butterworth WA, Meyer J, et al. A systematic review and meta-analysis of robotic-assisted transabdominal total mesorectal excision and transanal total mesorectal excision: which approach offers optimal short-term outcomes for mid-to-low rectal adenocarcinoma? Tech Coloproctol. 2021 Nov;25(11):1183-98. Abstract
365. Townsend AR, Chong LC, Karapetis C, et al. Selective internal radiation therapy for liver metastases from colorectal cancer. Cancer Treat Rev. 2016 Nov;50:148-54. Abstract
366. van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016 May 20;34(15):1723-31.Full text Abstract
367. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004 Nov 1;88(2):78-85. Abstract
368. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001 Dec;12(12):1711-20. Abstract
369. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010 Aug 10;28(23):3687-94.Full text Abstract
370. Mulcahy MF, Mahvash A, Pracht M, et al. Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol. 2021 Sep 20;JCO2101839.Full text Abstract
371. d'Andrea E, Russi M, Pacilio M, et al. Yttrium-90 radioembolization of colorectal cancer liver metastases: a systematic review of clinical evidence. Am J Clin Oncol. 2022 Apr 1;45(4):175-81. Abstract
372. Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017 Sep;18(9):1159-71.Full text Abstract
373. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: management of immunotherapy-related toxicities [internet publication].Full text
374. Morris VK, Kennedy EB, Baxter NN, et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol. 2023 Jan 20;41(3):678-700.Full text Abstract
375. Vogelbaum MA, Brown PD, Messersmith H, et al. Treatment for brain metastases: ASCO-SNO-ASTRO guideline. J Clin Oncol. 2022 Feb 10;40(5):492-516.Full text Abstract
376. Ligibel JA, Bohlke K, May AM, et al. Exercise, diet, and weight management during cancer treatment: ASCO guideline. J Clin Oncol. 2022 Aug 1;40(22):2491-507.Full text Abstract
377. Hardiman KM, Felder SI, Friedman G, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the surveillance and survivorship care of patients after curative treatment of colon and rectal cancer. Dis Colon Rectum. 2021 May;64(5):517-33.Full text Abstract
378. You YN, Hardiman KM, Bafford A, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of rectal cancer. Dis Colon Rectum. 2020 Sep;63(9):1191-222.Full text Abstract
379. Kahi CJ, Boland CR, Dominitz JA, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2016 Mar;111(3):337-46.Full text Abstract
380. El-Shami K, Oeffinger KC, Erb NL, et al. American Cancer Society colorectal cancer survivorship care guidelines. CA Cancer J Clin. 2015 Nov-Dec;65(6):428-55.Full text Abstract
381. Zerey M, Hawver LM, Awad Z, et al; Members of the SAGES Guidelines Committee. SAGES evidence-based guidelines for the laparoscopic resection of curable colon and rectal cancer. Surg Endosc. 2013 Jan;27(1):1-10.Full text Abstract
382. Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Jan;34(1):10-32.Full text Abstract
383. Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Oct;31(10):1291-305.Full text Abstract
384. Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-38.Full text Abstract
385. Stjepanovic N, Moreira L, Carneiro F, et al; ESMO Guidelines Committee. Hereditary gastrointestinal cancers: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 Oct 1;30(10):1558-71.Full text Abstract
386. Scottish Intercollegiate Guidelines Network. Diagnosis and management of colorectal cancer: a national clinical guideline. Aug 2016 [internet publication].Full text
387. Heresbach D, Manfredi S, D'halluin PN, et al. Review in depth and meta-analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol. 2006 Apr;18(4):427-33. Abstract
388. Burch JA, Soares-Weiser K, St John DJ, et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review. J Med Screen. 2007;14(3):132-7.Full text Abstract
389. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5.Full text Abstract
390. Li X, Fu R, Ni H, et al. Effect of neoadjuvant therapy on the functional outcome of patients with rectal cancer: a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2023 Feb;35(2):e121-34. Abstract
391. Ryoo SB. Low anterior resection syndrome. Ann Gastroenterol Surg. 2023 Sep;7(5):719-24.Full text Abstract
392. Gebremedhn EG, Shortland PJ, Mahns DA. The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review. BMC Cancer. 2018 Apr 12;18(1):410.Full text Abstract
393. Lee S, Ma C, Shi Q, et al. Potential mediators of oxaliplatin-induced peripheral neuropathy from adjuvant therapy in stage III colon cancer: findings from CALGB (Alliance)/SWOG 80702. J Clin Oncol. 2023 Feb 10;41(5):1079-91.Full text Abstract
394. Stintzing S, Kapaun C, Laubender RP, et al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer. 2012 Jun 26;132(1):236-45.Full text Abstract
395. Patel SV, Liberman SA, Burgess PL, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the reduction of venous thromboembolic disease in colorectal surgery. Dis Colon Rectum. 2023 Sep 1;66(9):1162-73.Full text Abstract
396. Emoto S, Nozawa H, Kawai K, et al. Venous thromboembolism in colorectal surgery: incidence, risk factors, and prophylaxis. Asian J Surg. 2019 Sep;42(9):863-73.Full text Abstract
397. Patel SV, Zhang L, Wei XS, et al. A population-based cohort study of venous thromboembolism rates following surgery and during adjuvant chemotherapy in patients with colon cancer. Dis Colon Rectum. 2020 Mar;63(3):336-45.Full text Abstract
398. Gupta S, Lieberman D, Anderson JC, et al. Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2020 Mar;115(3):415-34.Full text Abstract
399. Hassan C, Antonelli G, Dumonceau JM, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) guideline - update 2020. Endoscopy. 2020 Aug;52(8):687-700.Full text Abstract
400. Liu F, Wang LL, Liu XR, et al. Risk factors for radical rectal cancer surgery with a temporary stoma becoming a permanent stoma: a pooling up analysis. J Laparoendosc Adv Surg Tech A. 2023 Aug;33(8):743-9. Abstract
401. Geng L, Li X, Guo L, et al. The content and effectiveness of physical activity for cancer-related fatigue among colorectal cancer survivors: systematic review and meta-analysis. Nurs Open. 2023 Jul;10(7):4274-85.Full text Abstract
402. Brown JC, Ma C, Shi Q, et al. Physical activity in stage III colon cancer: CALGB/SWOG 80702 (alliance). J Clin Oncol. 2023 Jan 10;41(2):243-54.Full text Abstract
403. Brown JC, Ma C, Shi Q, et al. Inflammation, physical activity, and disease-free survival in stage III colon cancer: cancer and Leukemia Group B-Southwest Oncology Group 80702 (Alliance). J Natl Cancer Inst. 2024 Dec 1;116(12):2032-9.Full text Abstract
404. Veettil SK, Lim KG, Ching SM, et al. Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials. BMC Cancer. 2017 Nov 14;17(1):763.Full text Abstract
405. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012 Oct 25;367(17):1596-606.Full text Abstract
406. Dulai PS, Singh S, Marquez E, et al. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. BMJ. 2016 Dec 5;355:i6188.Full text Abstract
407. Hua X, Phipps AI, Burnett-Hartman AN, et al. Timing of aspirin and other nonsteroidal anti-inflammatory drug use among patients with colorectal cancer in relation to tumor markers and survival. J Clin Oncol. 2017 Aug 20;35(24):2806-13. Abstract
Use of this content is subject to our disclaimer